PURPOSE: We aimed to outline the existing information and the underlying mechanisms of risk of falls associated with the use of urinary antimuscarinics for overactive bladder (OAB) or alpha-blockers for benign prostatic hyperplasia (BPH) in older adults. In addition, we aimed to provide assistance to clinicians in decision-making about (de-)prescribing these drugs in older adults. METHODOLOGY: Based on a literature search in PubMed and Google Scholar, we reviewed the literature, and identified additional relevant articles from reference lists, with an emphasis on the most commonly prescribed drugs in OAB and BPH in older patients. We discussed the use of bladder antimuscarinics and alpha-blockers, their potential side effects related to falls, and the deprescribing of these drugs in older adults. RESULTS: Urinary urgency or incontinence and lower urinary tract symptoms due to untreated OAB and BPH contribute to fall risk. On the other hand, the use of bladder antimuscarinics and alpha-blockers is also related to fall risk. They contribute to (or cause) falling through dizziness, somnolence, visual impairment, and orthostatic hypotension while they differ in their side-effect profiles regarding these problems. Falls are common and can cause a remarkable amount of morbidity and mortality. Thus, preventive measures should be taken to lower the risk. If the clinical condition allows, withdrawal of bladder antimuscarinics and alpha-blockers is recommended in fall-prone older adults. There are practical resources and algorithms that guide and assist clinicians in deprescribing these drug groups. CONCLUSIONS: The decision to prescribe or deprescribe these treatments in patients at high risk of falls should be individualized. In addition to explicit tools that are helpful for clinical decision-making in (de-)prescribing these drugs, STOPPFall (a recently developed expert-based decision aid specifically aiming to prevent falls) is present to assist prescribers in attaining decisions.

Department of Geriatric Medicine 1st Faculty of Medicine Charles University and General University Hospital Prague and Faculty of Health and Social Sciences University of South Bohemia České Budejovice Czechia

Division of Geriatrics Department of Internal Medicine Istanbul Medical School Istanbul University Istanbul Turkey

Geriatrics Clinic Tekirdağ Dr Ismail Fehmi Cumalıoglu City Hospital Tekirdağ Turkey

Internal Medicine and Geriatrics Clinic Liv Hospital Vadi Istanbul Istanbul Turkey

Zobrazit více v PubMed

Deandrea S, Lucenteforte E, Bravi F et al (2010) Risk factors for falls in community-dwelling older people: a systematic review and meta-analysis. Epidemiology 21:658–668 PubMed DOI

Al-Aama T (2011) Falls in the elderly: spectrum and prevention. Can Fam Physician 57:771–776 PubMed PMC

Chiara M, Gianluigi G, Pasquale A et al (2013) Unexplained falls are frequent in patients with fall-related injury admitted to orthopaedic wards: the UFO study (unexplained falls in older patients). Curr Gerontol Geriatr Res 2013:928603 PubMed DOI PMC

National Institute for Health and Care Excellence (NICE) (2015) Falls in older people

Abrams P, Cardozo L, Fall M et al (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61:37–49 PubMed DOI

Shaw C, Wagg A (2020) Overactive bladder in frail older adults. Drugs Aging 37:559–565 PubMed DOI

Thom D (1998) Variation in estimates of urinary incontinence prevalence in the community: effects of differences in definition, population characteristics, and study type. J Am Geriatr Soc 46:473–480 PubMed DOI

Nakagawa H, Niu K, Hozawa A et al (2010) Impact of nocturia on bone fracture and mortality in older individuals: a Japanese longitudinal cohort study. J Urol 184:1413–1418 PubMed DOI

Jayadevappa R, Chhatre S, Newman DK et al (2018) Association between overactive bladder treatment and falls among older adults. Neurourol Urodyn 37:2688–2694 PubMed DOI

Wagg AS CL, Johnson T et al (2017) Incontinence in the frail elderly. In: Abrams P CL, Wagg A, Wein A (eds) Incontinence, 6th Edition

Chuang CC, Yang E, Zou KH et al (2019) Health and functional status, health events, use of healthcare services and costs associated with overactive bladder among the medically complex vulnerable elderly in the US. Int J Clin Pract 73:e13207 PubMed DOI

Brown JS, Vittinghoff E, Wyman JF et al (2000) Urinary incontinence: does it increase risk for falls and fractures? Study of osteoporotic fractures research group. J Am Geriatr Soc 48:721–725 PubMed DOI

Szabo SM, Gooch KL, Walker DR et al (2018) The association between overactive bladder and falls and fractures: a systematic review. Adv Ther 35:1831–1841 PubMed DOI PMC

Josephson KLGD (2004) Key considerations when treating the older patient with symptoms of urinary frequency and urgency. Ann Long-Term Care 12:2

Green AR, Reifler LM, Boyd CM et al (2018) Medication profiles of patients with cognitive impairment and high anticholinergic burden. Drugs Aging 35:223–232 PubMed DOI PMC

Kachru N, Holmes HM, Johnson ML et al (2021) Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study. Curr Med Res Opin 37:1303–1313 PubMed DOI PMC

Sura S, Aparasu R (2019) PUK19 overactive bladder patients in the nursing homes: resident characteristics and treatment pattern. Value in Health 22:S384 DOI

Wagg A (2018) Anticholinergics for overactive bladder in frail and medically complex older people: the case for. Drugs Aging 35:777–780 PubMed DOI

Boyle P, Napalkov P (1995) The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol Suppl 168:7–12 PubMed

Committee AUAPG. 2003 AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 170: 530–547

Parsons JK, Mougey J, Lambert L et al (2009) Lower urinary tract symptoms increase the risk of falls in older men. BJU Int 104:63–68 PubMed DOI PMC

Feldstein C, Weder AB (2012) Orthostatic hypotension: a common, serious and underrecognized problem in hospitalized patients. J Am Soc Hypertens 6:27–39 PubMed DOI

Lavsa SM, Fabian TJ, Saul MI et al (2010) Influence of medications and diagnoses on fall risk in psychiatric inpatients. Am J Health Syst Pharm 67:1274–1280 PubMed DOI

Poon IO, Braun U (2005) High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans. J Clin Pharm Ther 30:173–178 PubMed DOI

Bertaccini A, Vassallo F, Martino F et al (2001) Symptoms, bothersomeness and quality of life in patients with LUTS suggestive of BPH. Eur Urol 40(Suppl 1):13–18 PubMed DOI

Lukacz ES (2021) Urgency urinary incontinence/overactive bladder (OAB) in females: Treatment. In. UpToDate

Clinical Consensus Statement (2021) Association of anticholinergic medication use and cognition in women with overactive bladder. Female Pelvic Med Reconstr Surg 27:69–71 DOI

Fogaing C, Mossa AH, Campeau L (2020) Are beta 3 adrenergic agonists now the preferred pharmacologic management of overactive bladder? Curr Urol Rep 21:49 PubMed DOI

From the American Association of Neurological Surgeons ASoNC, Interventional Radiology Society of Europe CIRACoNSESoMINTESoNESOSfCA, Interventions SoIRSoNS et al (2018) Multisociety consensus quality improvement revised consensus statement for endovascular therapy of acute ischemic stroke. Int J Stroke 13: 612–632

Kachru N, Holmes HM, Johnson ML et al (2020) Risk of mortality associated with non-selective antimuscarinic medications in older adults with dementia: a retrospective study. J Gen Intern Med 35:2084–2093 PubMed DOI PMC

Andersson KE (2017) On the site and mechanism of action of beta3-adrenoceptor agonists in the bladder. Int Neurourol J 21:6–11 PubMed DOI PMC

Griebling TL, Campbell NL, Mangel J et al (2020) Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR). BMC Geriatr 20:109 PubMed DOI PMC

Nambiar AK, Bosch R, Cruz F et al (2018) EAU guidelines on assessment and nonsurgical management of urinary incontinence. Eur Urol 73:596–609 PubMed DOI

Lightner DJ, Gomelsky A, Souter L, Vasavada SP (2019) Diagnosis and treatment of overactive bladder (Non-neurogenic) in adults: AUA/SUFU guideline amendment 2019. J Urol 202:558–563 PubMed DOI

Kistler KD, Xu Y, Zou KH et al (2018) Systematic literature review of clinical trials evaluating pharmacotherapy for overactive bladder in elderly patients: an assessment of trial quality. Neurourol Urodyn 37:54–66 PubMed DOI

Buser N, Ivic S, Kessler TM et al (2012) Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses. Eur Urol 62:1040–1060 PubMed DOI

Chapple C, Schneider T, Haab F et al (2014) Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial. BJU Int 114:418–426 PubMed

Kaplan SA, Cardozo L, Herschorn S et al (2014) Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER. Int J Clin Pract 68:1065–1073 PubMed DOI

Stewart W, Corey R, Herzog A et al (2001) Prevalence of overactive bladder in women: results from the NOBLE program. Int Urogynecol J 12:S66

Rosa GM, Bauckneht M, Scala C et al (2013) Cardiovascular effects of antimuscarinic agents in overactive bladder. Expert Opin Drug Saf 12:815–827 PubMed DOI

Abrams P, Andersson KE (2007) Muscarinic receptor antagonists for overactive bladder. BJU Int 100:987–1006 PubMed DOI

Chancellor M, Boone T (2012) Anticholinergics for overactive bladder therapy: central nervous system effects. CNS Neurosci Ther 18:167–174 PubMed DOI

Ishizaka N, Noda M, Yokoyama S et al (1998) Muscarinic acetylcholine receptor subtypes in the human iris. Brain Res 787:344–347 PubMed DOI

Andersson KE, Campeau L, Olshansky B (2011) Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction. Br J Clin Pharmacol 72:186–196 PubMed DOI PMC

Griebling TL, Campbell NL, Mangel J et al (2020) Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR). BMC Geriatr 20:1–10 DOI

By the American Geriatrics Society Beers Criteria Update Expert P. American Geriatrics Society (2019) Updated AGS beers criteria(R) for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2019(67):674–694

O’Mahony D, O’Sullivan D, Byrne S et al (2014) STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing 44:213–218 PubMed DOI PMC

Bahat G, Ilhan B, Erdogan T et al (2020) Turkish inappropriate medication use in the elderly (TIME) criteria to improve prescribing in older adults: TIME-to-STOP/TIME-to-START. Eur Geriatr Med 11:491–498 PubMed DOI PMC

Bahat G, Ilhan B, Erdogan T et al (2021) International validation of the Turkish inappropriate medication use in the elderly (time) criteria set: a Delphi panel study. Drugs Aging 38:513–521 PubMed DOI PMC

Moga DC, Carnahan RM, Lund BC et al (2013) Risks and benefits of bladder antimuscarinics among elderly residents of Veterans Affairs Community Living Centers. J Am Med Dir Assoc 14:749–760 PubMed DOI

Lackner TE, Wyman JF, McCarthy TC et al (2008) Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. J Am Geriatr Soc 56:862–870 PubMed DOI

Green AR, Segal J, Boyd CM et al (2020) Patterns of potentially inappropriate bladder antimuscarinic use in people with dementia: a retrospective cohort study. Drugs-Real World Outcomes 7:151–159 PubMed DOI PMC

Kao LT, Huang CY, Lin HC, Chu CM (2018) No increased risk of fracture in patients receiving antimuscarinics for overactive bladder syndrome: a retrospective cohort study. J Clin Pharmacol 58:727–732 PubMed DOI

Kachru N, Holmes HM, Johnson ML et al (2021) Comparative risk of adverse outcomes associated with nonselective and selective antimuscarinic medications in older adults with dementia and overactive bladder. Int J Geriatr Psychiatry 36:684–696 PubMed DOI

Yang N, Wu Q, Xu F, Zhang X (2021) Comparisons of the therapeutic safety of seven oral antimuscarinic drugs in patients with overactive bladder: a network meta-analysis. J Int Med Res 49:03000605211042994 PubMed DOI PMC

Mostafaei H, Salehi-Pourmehr H, Jilch S et al (2021) Choosing the most efficacious and safe oral treatment for idiopathic overactive bladder: a systematic review and network meta-analysis. Eur Urol Focus

Vouri SM, Kebodeaux CD, Stranges PM, Teshome BF (2017) Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: a systematic review and meta-analysis. Arch Gerontol Geriatr 69:77–96 PubMed DOI

Andersson KE, Sarawate C, Kahler KH et al (2010) Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder. BJU Int 106:268–274 PubMed DOI

Harvey RD (2012) Muscarinic receptor agonists and antagonists: effects on cardiovascular function. Muscarin Recep 2:299–316 DOI

Leone Roberti Maggiore U, Salvatore S, Alessandri F et al (2012) Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females. Exp Opin Drug Metab Toxicol 8:1387–1408 DOI

Serra DB, Affrime MB, Bedigian MP et al (2005) QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder. J Clin Pharmacol 45:1038–1047 PubMed DOI

Nitti VW, Dmochowski R, Sand PK et al (2007) Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol 178:2488–2494 PubMed DOI

Malhotra B, Wood N, Sachse R, Gandelman K (2010) Thorough QT study of the effect of fesoterodine on cardiac repolarization. Int J Clin Pharmacol Ther 48:309–318 PubMed DOI

Guay DR (2005) Trospium chloride: an update on a quaternary anticholinergic for treatment of urge urinary incontinence. Ther Clin Risk Manag 1:157 PubMed DOI PMC

Hussain R, Hartigan-Go K, Thomas S, Ford G (1996) Effect of oxybutynin on the QTc interval in elderly patients with urinary incontinence. Br J Clin Pharmacol 41:73–75 PubMed DOI

Jones SE, Kasamaki Y, Shuba LM et al (2000) Analysis of the electrophysiologic effects of short-term oxybutynin on guinea pig and rabbit ventricular cells. J Cardiovasc Pharmacol 35:334–340 PubMed DOI

Asajima H, Sekiguchi Y, Matsushima S et al (2008) QT prolongation and torsade de pointes associated with solifenacin in an 81-year-old woman. Br J Clin Pharmacol 66:896 PubMed DOI PMC

Hoffstetter S, Che LF (2009) Solifenacin succinate for the treatment of overactive bladder. Expert Opin Drug Metab Toxicol 5:345–350 PubMed DOI

Kang J, Chen X-L, Wang H et al (2004) Cardiac ion channel effects of tolterodine. J Pharmacol Exp Ther 308:935–940 PubMed DOI

Malhotra B, Glue P, Sweeney K et al (2007) Thorough QT study with recommended and supratherapeutic doses of tolterodine. Clin Pharmacol Ther 81:377–385 PubMed DOI

Garfinkel D, Ilhan B, Bahat G (2015) Routine deprescribing of chronic medications to combat polypharmacy. Therap Adv Drug Safety 6:212–233 DOI

Carnahan RM, Lund BC, Perry PJ, Chrischilles EA (2004) The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice? J Am Geriatr Soc 52:2082–2087 PubMed DOI

Sink KM, Thomas J III, Xu H et al (2008) Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. J Am Geriatr Soc 56:847–853 PubMed DOI PMC

Tannenbaum C, Johnell K (2014) Managing therapeutic competition in patients with heart failure, lower urinary tract symptoms and incontinence. Drugs Aging 31(2):93–101. https://doi.org/10.1007/s40266-013-0145-1 PubMed DOI

Srikrishna S, Robinson D, Cardozo L (2014) Important drug–drug interactions for treatments that target overactive bladder syndrome. Int Urogynecol J 25:715–720 PubMed DOI

Athanasopoulos A, Giannitsas K (2011) An overview of the clinical use of antimuscarinics in the treatment of overactive bladder. Adv Urol 20:11

Trospium: Drug information, Lexicomp Online. In. 2022

Seppala LJ, Petrovic M, Ryg J et al (2021) STOPPFall (screening tool of older persons prescriptions in older adults with high fall risk): a Delphi study by the EuGMS task and finish group on fall-risk-increasing drugs. Age Ageing 50:1189–1199 PubMed DOI

Pazan F, Weiss C, Wehling M (2022) The FORTA (Fit fOR The Aged) list 2021: fourth version of a validated clinical aid for improved pharmacotherapy in older adults. Drugs Aging 39(3):245–247. https://doi.org/10.1007/s40266-022-00922-5 PubMed DOI PMC

Oelke M, Becher K, Castro-Diaz D, Chartier-Kastler E, Kirby M, Wagg A, Wehling M (2015) Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014). Age Ageing 44(5):745–755. https://doi.org/10.1093/ageing/afv077 PubMed DOI PMC

Ha M, Furman A, Al Rihani SB et al (2022) Pharmacist‐driven interventions to de‐escalate urinary antimuscarinics in the Programs of All‐Inclusive Care for the Elderly. J Am Geriatr Soc

Deprescribing guide for anticholinergic drugs for urinary incontinence. The NSW Therapeutic Advisory Group. In. 2022.

Gravas SC, Gacci JN, Gratzke M, Herrmann C, Mamoulakis TRW, Rieken C, Speakman M, Tikkinen MJ, KAO (2022) EAU guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). European Association of Urology 2022. In 2022 Edition

McVary KT (2022) Medical treatment of benign prostatic hyperplasia. In: O'Leary MPGJ (ed) Uptodate. pp 1–2

Djavan B, Chapple C, Milani S, Marberger M (2004) State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 64:1081–1088 PubMed DOI

Barendrecht MM, Abrams P, Schumacher H et al (2008) Do α1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance? Neurourol Urodyn 27:226–230 PubMed DOI

McConnell JD, Roehrborn CG, Bautista OM et al (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387–2398 PubMed DOI

Boyle P, Robertson C, Manski R et al (2001) Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. Urology 58:717–722 PubMed DOI

Roehrborn C (2006) Three months’ treatment with the α1-blocker alfuzosin does not affect total or transition zone volume of the prostate. Prostate Cancer Prostatic Dis 9:121–125 PubMed DOI

Roehrborn CG, Siami P, Barkin J et al (2008) The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 179:616–621 PubMed DOI

Roehrborn CG, Siami P, Barkin J et al (2010) The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 57:123–131 PubMed DOI

(2022) Duloxetin, terazosin, alfuzosin, silodosin: drug information, lexicomb. Online

Vaughan CP, Brown CJ, Goode PS et al (2010) The association of nocturia with incident falls in an elderly community-dwelling cohort. Int J Clin Pract 64:577–583 PubMed DOI

Temml C, Ponholzer A, Gutjahr G et al (2009) Nocturia is an age-independent risk factor for hip-fractures in men. Neurourol Urodyn 28:949–952 PubMed DOI

Welk B, McArthur E, Fraser L-A et al (2015) The risk of fall and fracture with the initiation of a prostate-selective α antagonist: a population based cohort study. BMJ 351:2

Lee M (2000) Tamsulosin for the treatment of benign prostatic hypertrophy. Ann Pharmacother 34:188–199 PubMed DOI

Roehrborn CG, Van Kerrebroeck P, Nordling J (2003) Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 92:257–261 PubMed DOI

Marks LS, Gittelman MC, Hill LA et al (2009) Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol 181:2634–2640 PubMed DOI

Nickel J, Sander S, Moon T (2008) A meta-analysis of the vascular-related safety profile and efficacy of α-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract 62:1547–1559 PubMed DOI

Barendrecht MM, Koopmans RP, De La Rosette JJ, Michel MC (2005) Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system. BJU Int 95:19–28 PubMed DOI

Nieminen T, Tammela TL, Koobi T, Kahonen M (2006) The effects of tamsulosin and sildenafil in separate and combined regimens on detailed hemodynamics in patients with benign prostatic enlargement. J Urol 176:2551–2556 PubMed DOI

Chapple CR, Montorsi F, Tammela TL et al (2011) Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol 59:342–352 PubMed DOI

Novara G, Chapple CR, Montorsi F (2014) A pooled analysis of individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH). BJU Int 114:427–433 PubMed

Yu HJ, Lin ATL, Yang SSD et al (2011) Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). BJU Int 108:1843–1848 PubMed DOI